应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
01513 丽珠医药
已收盘 04-09 16:08:13
29.400
+0.340
+1.17%
最高
30.400
最低
29.060
成交量
184.70万
今开
29.080
昨收
29.060
日振幅
4.61%
总市值
261.07亿
流通市值
88.20亿
总股本
8.88亿
成交额
5,496万
换手率
0.62%
流通股本
3.00亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
港股创新药概念股盘初走高!丽珠医药涨超4%,歌礼制药涨超3%
老虎资讯综合 · 09:37
港股创新药概念股盘初走高!丽珠医药涨超4%,歌礼制药涨超3%
丽珠医药(01513.HK)拟4月10日举办2025年年度报告业绩说明会
中金财经 · 04-01
丽珠医药(01513.HK)拟4月10日举办2025年年度报告业绩说明会
丽珠医药3月无新增发行或股份变动
公告速递 · 04-01
丽珠医药3月无新增发行或股份变动
丽珠医药(01513)将于股东大会审议后派发2025年度股息每股1.43元
公告速递 · 03-26
丽珠医药(01513)将于股东大会审议后派发2025年度股息每股1.43元
丽珠医药(01513):注射用布瑞哌唑微球获得药物临床试验批准通知书
智通财经 · 03-26
丽珠医药(01513):注射用布瑞哌唑微球获得药物临床试验批准通知书
丽珠医药将于派息日有待公布派发末期股息每股1.43元
公告速递 · 03-24
丽珠医药将于派息日有待公布派发末期股息每股1.43元
丽珠医药(01513)将派发末期股息每10股14.3元
智通财经 · 03-24
丽珠医药(01513)将派发末期股息每10股14.3元
丽珠医药(01513):冉永梅获委任为董事会战略委员会委员
智通财经 · 03-24
丽珠医药(01513):冉永梅获委任为董事会战略委员会委员
丽珠医药(01513):收入稳步增长,核心业务板块分化明显,治理与风险管理持续完善
公告速递 · 03-24
丽珠医药(01513):收入稳步增长,核心业务板块分化明显,治理与风险管理持续完善
丽珠医药(01513)拟使用不超过25亿元的闲置自有资金购买委托理财产品
智通财经 · 03-24
丽珠医药(01513)拟使用不超过25亿元的闲置自有资金购买委托理财产品
业绩乏力,丽珠医药高管大换血
蓝鲸财经 · 03-12
业绩乏力,丽珠医药高管大换血
丽珠医药03月11日遭主力抛售65.2万元
市场透视 · 03-11
丽珠医药03月11日遭主力抛售65.2万元
每日卖空追踪 | 丽珠医药 03月09日卖空量成交8.55万股,卖空比例为7.21%
市场透视 · 03-09
每日卖空追踪 | 丽珠医药 03月09日卖空量成交8.55万股,卖空比例为7.21%
丽珠医药03月09日主力净流入54.7万元 散户资金抛售
市场透视 · 03-09
丽珠医药03月09日主力净流入54.7万元 散户资金抛售
丽珠医药(01513)拟公开要约收购IMP股份事宜正式收到越南国家证券委员会出具的同意本次交易的批复文件
智通财经 · 03-06
丽珠医药(01513)拟公开要约收购IMP股份事宜正式收到越南国家证券委员会出具的同意本次交易的批复文件
丽珠医药(01513)拟对越南IMP发起公开要约收购 获当地监管正式批复
公告速递 · 03-06
丽珠医药(01513)拟对越南IMP发起公开要约收购 获当地监管正式批复
每日卖空追踪 | 丽珠医药 03月05日卖空量成交7.1万股,卖空比例为5.84%
市场透视 · 03-05
每日卖空追踪 | 丽珠医药 03月05日卖空量成交7.1万股,卖空比例为5.84%
每日卖空追踪 | 丽珠医药 03月04日卖空量成交6.32万股,卖空比例为7.89%
市场透视 · 03-04
每日卖空追踪 | 丽珠医药 03月04日卖空量成交6.32万股,卖空比例为7.89%
丽珠医药(01513)2026年2月股份变动月报:股本维持不变
公告速递 · 03-02
丽珠医药(01513)2026年2月股份变动月报:股本维持不变
丽珠医药(01513.HK)3月24日举行董事会会议审议及批准全年业绩
中金财经 · 03-02
丽珠医药(01513.HK)3月24日举行董事会会议审议及批准全年业绩
暂无数据
公司概况
公司名称:
丽珠医药
所属市场:
SEHK
上市日期:
--
主营业务:
丽珠医药集团股份有限公司是一家主要从事医药产品的研发、生产及销售业务的中国公司。该公司的主要业务包括化学制剂、生物制品、原料药及中间体、中药制剂、诊断试剂和设备,以及商业发展和职能管理。该公司的主要产品品牌包括“壹丽安”(艾普拉唑肠溶片及注射用艾普拉唑钠)、“丽珠得乐”(枸橼酸铋钾)系列产品、“丽倍乐”(雷贝拉唑钠肠溶胶囊)、“维三联”(枸橼酸铋钾片/替硝唑片/克拉霉素片)、“贝依”(注射用醋酸亮丙瑞林微球)、“丽申宝”(注射用尿促卵泡素)、“乐宝得”(注射用尿促性素)、“丽福康”(注射用伏立康唑)等。该公司主要在中国国内和海外市场开展业务。
发行价格:
--
{"stockData":{"symbol":"01513","market":"HK","secType":"STK","nameCN":"丽珠医药","latestPrice":29.4,"timestamp":1775722093005,"preClose":29.06,"halted":0,"volume":1846964,"delay":0,"changeRate":0.011699931176875426,"floatShares":300000000,"shares":888000000,"eps":2.599798660347056,"marketStatus":"已收盘","change":0.34,"latestTime":"04-09 16:08:13","open":29.08,"high":30.4,"low":29.06,"amount":54961217,"amplitude":0.046111,"askPrice":29.46,"askSize":4700,"bidPrice":29.4,"bidSize":2100,"shortable":3,"etf":0,"ttmEps":2.599798660347056,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1775784600000},"marketStatusCode":5,"adr":0,"listingDate":1389801600000,"exchange":"SEHK","adjPreClose":29.06,"dividendRate":0.040774,"openAndCloseTimeList":[[1775698200000,1775707200000],[1775710800000,1775721600000]],"volumeRatio":1.541088,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"000513","market":"SZ","secType":"STK","nameCN":"丽珠集团","latestPrice":34.27,"timestamp":1775718000000,"preClose":34.53,"halted":0,"volume":6325300,"delay":0,"premium":"-25.09"}},"requestUrl":"/m/hq/s/01513/tweets","defaultTab":"tweets","newsList":[{"id":"1179745077","title":"港股创新药概念股盘初走高!丽珠医药涨超4%,歌礼制药涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1179745077","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179745077?lang=zh_cn&edition=full","pubTime":"2026-04-09 09:37","pubTimestamp":1775698645,"startTime":"0","endTime":"0","summary":"创新药概念股盘初走高,$丽珠医药(01513)$涨超4%,$歌礼制药-B(01672)$、$康诺亚-B(02162)$涨超3%,$翰森制药(03692)$、$信达$、生物(01801)$、$药明康德(02359)$涨超2%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","01513","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624518996","title":"丽珠医药(01513.HK)拟4月10日举办2025年年度报告业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2624518996","media":"中金财经","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624518996?lang=zh_cn&edition=full","pubTime":"2026-04-01 19:37","pubTimestamp":1775043422,"startTime":"0","endTime":"0","summary":"格隆汇4月1日丨丽珠医药(01513.HK)公告,为了加强与公司投资者,特别是中小投资者的沟通和交流,进一步了解公司经营业绩及未来发展情况,公司将于2026年4月10日(星期五)15:00至17:00在全景网举办公司2025年年度报告业绩说明会,本次业绩说明会将采用网络远程的方式举行,投资者可登录全景网“投资者关系互动平台”(http://ir.p5w.net)参与本次业绩说明会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260401/32119243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1191","01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164443248","title":"丽珠医药3月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1164443248","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164443248?lang=zh_cn&edition=full","pubTime":"2026-04-01 17:26","pubTimestamp":1775035607,"startTime":"0","endTime":"0","summary":"丽珠医药集团股份有限公司(股票代码:01513)于2026年4月1日发布截至2026年3月31日的股份变动月报表,报告期内公司股本结构保持稳定,未有新增发行、购回或注销记录。\n公告显示,截至3月末,公司注册股本总额为人民币887,907,171元。其中,H股数量为299,807,117股,A股数量为588,100,054股,均与上月底持平。此外,报告期内未发生任何期权、股权激励及可换股债券等变动事项。\n综合本次月报情况,公司股本规模维持不变。公司同时确认遵守香港联交所《上市规则》及相关法律监管要求。公告由公司秘书刘宁签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192824611","title":"丽珠医药(01513)将于股东大会审议后派发2025年度股息每股1.43元","url":"https://stock-news.laohu8.com/highlight/detail?id=1192824611","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192824611?lang=zh_cn&edition=full","pubTime":"2026-03-26 20:06","pubTimestamp":1774526783,"startTime":"0","endTime":"0","summary":"丽珠医药(01513)公告显示,公司就截至2025年12月31日止年度的利润分配预案进行补充说明,拟以股权登记日的公司总股本为基数,每10股派发现金股利人民币14.30元(含税),即折合每股1.43元(含税),不送红股,也不以资本公积金转增股本。\n本次派息计划尚需提交公司2025年度股东大会审议批准。若获通过,公司将依照股权登记日确定的持股数量,向全体股东派付相应金额,具体派付日期及安排将另行公告。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622851296","title":"丽珠医药(01513):注射用布瑞哌唑微球获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2622851296","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622851296?lang=zh_cn&edition=full","pubTime":"2026-03-26 19:13","pubTimestamp":1774523600,"startTime":"0","endTime":"0","summary":"智通财经APP讯,丽珠医药 发布公告,近日,公司全资控股子公司珠海市丽珠微球科技有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,同意公司申报的注射用布瑞哌唑微球开展用于成人精神分裂症的临床试验。注射用布瑞哌唑微球为公司自主研发的缓释微球制剂,是新一代精神分裂症的治疗药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419676.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"丽珠医药(01513):注射用布瑞哌唑微球获得药物临床试验批准通知书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133668522","title":"丽珠医药将于派息日有待公布派发末期股息每股1.43元","url":"https://stock-news.laohu8.com/highlight/detail?id=1133668522","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133668522?lang=zh_cn&edition=full","pubTime":"2026-03-24 21:22","pubTimestamp":1774358520,"startTime":"0","endTime":"0","summary":"丽珠医药(01513)\n根据公司公告,丽珠医药集团股份有限公司2025年12月31日止年度拟派发末期股息,每10股派发14.3元人民币,折合每股1.43元人民币,最终派息金额以公司公布为准。\n本次股息派发仍须待股东批准,具体除净日、过户登记截止日期及派息日期尚未确定,相关信息将另行公告。公司拟派息货币为港币,实际金额及汇率亦有待公布。\n公司董事会成员包括执行董事唐阳刚先生,非执行董事朱保国先生、林楠棋先生及邱庆丰先生,职工董事冉永梅女士,以及独立非执行董事白华先生、罗会远先生、崔丽婕女士、王智瑶女士。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621060689","title":"丽珠医药(01513)将派发末期股息每10股14.3元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621060689","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621060689?lang=zh_cn&edition=full","pubTime":"2026-03-24 21:18","pubTimestamp":1774358282,"startTime":"0","endTime":"0","summary":"智通财经APP讯,丽珠医药(01513)发布公告,将派发截至2025年12月31日止年度末期股息每10股14.3元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418282.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01513","BK4585","VIG","BK4588","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621067093","title":"丽珠医药(01513):冉永梅获委任为董事会战略委员会委员","url":"https://stock-news.laohu8.com/highlight/detail?id=2621067093","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621067093?lang=zh_cn&edition=full","pubTime":"2026-03-24 21:07","pubTimestamp":1774357658,"startTime":"0","endTime":"0","summary":"智通财经APP讯,丽珠医药(01513)发布公告,于2026年3月24日,公司职工代表董事冉永梅女士已获委任为董事会战略委员会委员,执行董事唐阳刚先生已获委任为董事会提名委员会委员,自2026年3月24日起生效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418275.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134372153","title":"丽珠医药(01513):收入稳步增长,核心业务板块分化明显,治理与风险管理持续完善","url":"https://stock-news.laohu8.com/highlight/detail?id=1134372153","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134372153?lang=zh_cn&edition=full","pubTime":"2026-03-24 21:06","pubTimestamp":1774357563,"startTime":"0","endTime":"0","summary":"丽珠医药在报告期内的合并口径营业收入由人民币118.1234亿元上升至人民币120.2035亿元,同比增长1.76%。归属于公司股东的净利润为人民币20.2323亿元,同比下降1.84%;扣除非经常性损益后归属于公司股东的净利润为人民币20.0916亿元,同比上升1.51%。期内利润总额为人民币28.6205亿元,同比增长1.99%。经营活动产生的现金流量净额为人民币31.4504亿元,同比增长5.58%。综上所述,丽珠医药在本期实现了营业收入的总体稳步增长,净利润略有下滑但扣非后保持正向增长。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621062665","title":"丽珠医药(01513)拟使用不超过25亿元的闲置自有资金购买委托理财产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2621062665","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621062665?lang=zh_cn&edition=full","pubTime":"2026-03-24 20:29","pubTimestamp":1774355395,"startTime":"0","endTime":"0","summary":"智通财经APP讯,丽珠医药(01513)公布,公司及子公司拟使用不超过人民币25亿元(含)的闲置自有资金购买委托理财产品。在授权额度范围内,资金可滚动使用,任一时点使用闲置自有资金购买理财产品的投资总额(含前述投资的收益进行再投资的相关金额)不超过上述投资额度。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418234.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618750138","title":"业绩乏力,丽珠医药高管大换血","url":"https://stock-news.laohu8.com/highlight/detail?id=2618750138","media":"蓝鲸财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618750138?lang=zh_cn&edition=full","pubTime":"2026-03-12 18:14","pubTimestamp":1773310451,"startTime":"0","endTime":"0","summary":"不过,近年来,这家老牌制药企业出现业绩乏力,而高管团队的“新老交替”能否为这家企业带来新的生机引发业内关注。公开信息显示,丽珠医药业务高度聚焦制药,横跨化药、原料药、中药、生物药及诊断试剂五大领域。除了化学板块,丽珠医药2025年半年报显示,其原料药与中间体板块因头孢类产品受国内市场价格波动影响,整体收入同比下降5.65%;诊断试剂及设备板块也因呼吸道产品周期变化,在去年同期高基数基础上,收入同比下滑5.13%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1773309216313250615","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1191","01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618218940","title":"丽珠医药03月11日遭主力抛售65.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618218940","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618218940?lang=zh_cn&edition=full","pubTime":"2026-03-11 16:15","pubTimestamp":1773216920,"startTime":"0","endTime":"0","summary":"03月11日, 丽珠医药股价跌1.38%,报收28.52元,成交金额1766.3万元,换手率0.21%,振幅1.80%,量比0.58。丽珠医药今日主力资金净流出65.2万元,上一交易日主力净流出137.2万元。该股近5个交易日上涨3.64%,主力资金累计净流出266.3万元,其中1个交易日为股价下跌时净流入;近20日主力资金累计净流出1389.3万元,其中净流出天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311161613a460a799&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311161613a460a799&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618725629","title":"每日卖空追踪 | 丽珠医药 03月09日卖空量成交8.55万股,卖空比例为7.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618725629","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618725629?lang=zh_cn&edition=full","pubTime":"2026-03-09 16:30","pubTimestamp":1773045022,"startTime":"0","endTime":"0","summary":"丽珠医药北京时间03月09日,涨0.92%,卖空量成交8.55万股,较上一交易日增加98.38%更多个股卖空数据请看下面视窗:卖空数据是观测市场多空博弈的关键指标:短期可反映市场情绪,高卖空比例预示看空预期,但极端值可能触发轧空反弹;长期结合基本面恶化则预警下行风险。需注意其局限性:卖空行为包含对冲需求,未必单纯看空;机构可能通过衍生品做空未体现在数据中,且散户跟风易扭曲信号。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309163245a45ae686&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309163245a45ae686&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618297436","title":"丽珠医药03月09日主力净流入54.7万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2618297436","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618297436?lang=zh_cn&edition=full","pubTime":"2026-03-09 16:16","pubTimestamp":1773044163,"startTime":"0","endTime":"0","summary":"03月09日, 丽珠医药股价涨0.92%,报收28.66元,成交金额3363.8万元,换手率0.40%,振幅3.66%,量比1.19。丽珠医药今日主力资金净流入54.7万元,上一交易日主力净流出119.2万元。该股近5个交易日上涨2.42%,主力资金累计净流出282.4万元,其中2个交易日为股价下跌时净流入;近20日主力资金累计净流出1224.4万元,其中净流出天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309162159a45ada5c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309162159a45ada5c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01513","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617681094","title":"丽珠医药(01513)拟公开要约收购IMP股份事宜正式收到越南国家证券委员会出具的同意本次交易的批复文件","url":"https://stock-news.laohu8.com/highlight/detail?id=2617681094","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617681094?lang=zh_cn&edition=full","pubTime":"2026-03-06 18:56","pubTimestamp":1772794588,"startTime":"0","endTime":"0","summary":"本公司董事会欣然宣布,本公司境外全资子公司LIANSGP已根据本公司相关董事会决议,就本次拟公开要约收购IMP股份事宜向越南国家证券委员会提交相关申请,且已正式收到越南国家证券委员会出具的同意本次交易的批复文件。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411090.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["161027","BK1191","01513","FVNmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115663921","title":"丽珠医药(01513)拟对越南IMP发起公开要约收购 获当地监管正式批复","url":"https://stock-news.laohu8.com/highlight/detail?id=1115663921","media":"公告速递","labels":["corporation","merge","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115663921?lang=zh_cn&edition=full","pubTime":"2026-03-06 18:56","pubTimestamp":1772794581,"startTime":"0","endTime":"0","summary":"丽珠医药发布公告,旗下境外全资子公司LIAN SGP HOLDING PTE.LTD.已完成向越南国家证券委员会提交对Imexpharm Corporation股份的公开要约收购申请,并正式获得同意批复。丽珠医药在2025年5月22日及2025年12月30日召开董事会,审议通过收购及公开要约收购IMP股权相关议案。公司方面强调,本次交易后续进展仍受市场变化及相关审批程序等因素影响,存在不确定性。丽珠医药表示,将依据中国及香港等地相关法律和规则,及时履行所需的审批及信息披露义务。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617518577","title":"每日卖空追踪 | 丽珠医药 03月05日卖空量成交7.1万股,卖空比例为5.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617518577","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617518577?lang=zh_cn&edition=full","pubTime":"2026-03-05 16:30","pubTimestamp":1772699423,"startTime":"0","endTime":"0","summary":"丽珠医药北京时间03月05日,跌0.58%,卖空量成交7.1万股,较上一交易日减少33.71%更多个股卖空数据请看下面视窗:卖空数据是观测市场多空博弈的关键指标:短期可反映市场情绪,高卖空比例预示看空预期,但极端值可能触发轧空反弹;长期结合基本面恶化则预警下行风险。需注意其局限性:卖空行为包含对冲需求,未必单纯看空;机构可能通过衍生品做空未体现在数据中,且散户跟风易扭曲信号。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305163244a44ef690&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305163244a44ef690&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617162554","title":"每日卖空追踪 | 丽珠医药 03月04日卖空量成交6.32万股,卖空比例为7.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617162554","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617162554?lang=zh_cn&edition=full","pubTime":"2026-03-04 16:30","pubTimestamp":1772613021,"startTime":"0","endTime":"0","summary":"丽珠医药北京时间03月04日,跌1.15%,卖空量成交6.32万股,较上一交易日减少69.95%更多个股卖空数据请看下面视窗:卖空数据是观测市场多空博弈的关键指标:短期可反映市场情绪,高卖空比例预示看空预期,但极端值可能触发轧空反弹;长期结合基本面恶化则预警下行风险。需注意其局限性:卖空行为包含对冲需求,未必单纯看空;机构可能通过衍生品做空未体现在数据中,且散户跟风易扭曲信号。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304163246a44a6bd6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304163246a44a6bd6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125916061","title":"丽珠医药(01513)2026年2月股份变动月报:股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1125916061","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125916061?lang=zh_cn&edition=full","pubTime":"2026-03-02 17:11","pubTimestamp":1772442690,"startTime":"0","endTime":"0","summary":"丽珠医药集团股份有限公司于2026年3月2日披露2026年2月股份变动月报表。报告期为2026年2月1日至2026年2月28日,公司A股与H股已发行股本合计维持不变。公司注册股本方面,A股注册股数期末为588,100,054股,H股注册股数期末为299,807,117股,面值均为人民币1元;公司本月底法定注册股本总额为人民币887,907,171元,与上月相比无变化。截至2026年2月底,公司股本结构未发生实质变动,总股本维持不变。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616382139","title":"丽珠医药(01513.HK)3月24日举行董事会会议审议及批准全年业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2616382139","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616382139?lang=zh_cn&edition=full","pubTime":"2026-03-02 17:07","pubTimestamp":1772442422,"startTime":"0","endTime":"0","summary":"格隆汇3月2日丨丽珠医药(01513.HK)公布,定于2026年3月24日(星期二)举行董事会会议,藉以审议及批准公司及其附属公司截至2025年12月31日止年度的全年业绩,考虑建议派发末期股息(如适用)及处理其他事项(如有)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260302/32037850.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["01513","BK1191"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.livzon.com.cn","stockEarnings":[{"period":"1week","weight":0.0154},{"period":"1month","weight":0.014},{"period":"3month","weight":-0.0313},{"period":"6month","weight":-0.1577},{"period":"1year","weight":0.1783},{"period":"ytd","weight":0.0189}],"compareEarnings":[{"period":"1week","weight":0.0237},{"period":"1month","weight":0.0191},{"period":"3month","weight":-0.0098},{"period":"6month","weight":-0.0151},{"period":"1year","weight":0.2864},{"period":"ytd","weight":0.0102}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"丽珠医药集团股份有限公司是一家主要从事医药产品的研发、生产及销售业务的中国公司。该公司的主要业务包括化学制剂、生物制品、原料药及中间体、中药制剂、诊断试剂和设备,以及商业发展和职能管理。该公司的主要产品品牌包括“壹丽安”(艾普拉唑肠溶片及注射用艾普拉唑钠)、“丽珠得乐”(枸橼酸铋钾)系列产品、“丽倍乐”(雷贝拉唑钠肠溶胶囊)、“维三联”(枸橼酸铋钾片/替硝唑片/克拉霉素片)、“贝依”(注射用醋酸亮丙瑞林微球)、“丽申宝”(注射用尿促卵泡素)、“乐宝得”(注射用尿促性素)、“丽福康”(注射用伏立康唑)等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":0.001134},{"month":2,"riseRate":0.538462,"avgChangeRate":0.025407},{"month":3,"riseRate":0.538462,"avgChangeRate":0.022432},{"month":4,"riseRate":0.692308,"avgChangeRate":0.034389},{"month":5,"riseRate":0.416667,"avgChangeRate":0.013787},{"month":6,"riseRate":0.5,"avgChangeRate":0.000101},{"month":7,"riseRate":0.416667,"avgChangeRate":-0.018444},{"month":8,"riseRate":0.5,"avgChangeRate":0.000715},{"month":9,"riseRate":0.454545,"avgChangeRate":0.011936},{"month":10,"riseRate":0.363636,"avgChangeRate":-0.019823},{"month":11,"riseRate":0.583333,"avgChangeRate":0.03425},{"month":12,"riseRate":0.5,"avgChangeRate":-0.008149}],"exchange":"SEHK","name":"丽珠医药","nameEN":"LIVZON PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"丽珠医药(01513)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供丽珠医药(01513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"丽珠医药,01513,丽珠医药股票,丽珠医药股票老虎,丽珠医药股票老虎国际,丽珠医药行情,丽珠医药股票行情,丽珠医药股价,丽珠医药股市,丽珠医药股票价格,丽珠医药股票交易,丽珠医药股票购买,丽珠医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"丽珠医药(01513)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供丽珠医药(01513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}